Nuance Story
2023
2022
2021
2020
2019
2018
2015
2014
2023
Completed dosing of First Patient in Ensifentrine China Phase III Trial for COPD
2022
Launched Bentrio™ nasal spray in Hong Kong as Asia expansion strategy
Licensed in allergy / virus prevention nasal spray Bentrio™ from Altamira
IND approval for Ensifentrine China phase 1 / 3 clinical trials for COPD
2021
Licensed in First-in-Class COPD dual MOA PDE 3&4 inhibitor Ensifentrine from Verona Pharma
Licensed in neonatal RDS drug / device combo Aerofact™ from Aerogen Pharma
Acquired Sino Health (Yinglian) with access to 4 commercial products in emergency care and a GSP license
2020
Licensed in post-operative pain product Ketorolac (NTM-001) from Neumentum
Raised US$ 181 million Series D equity funding
2019
Acquired NIFEREX Iron Polysaccharide Complex Capsules
2018
Established exclusive partnership with Aerogen Pharma on nebulizer device
Accumulatively raised US$ 80 million equity funding
2015
Established Commercial Platform for footprint in China
2014
Mr. Mark Lotter founded Nuance Pharma in Shanghai